BioSpace News Archive

Veracyte, Inc. (Nasdaq: VCYT) announced that data published in the journal Cancer show the ability of a novel gene expression signature to classify prostate cancer into distinct molecular subtypes that may inform which tumors are more likely to respond to different treatments.

Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 10:00 a.m. PT.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, announced that the company is scheduled to speak at the following upcoming financial conference.

Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 6,875,000 shares of its common stock at a public offering price of $8.00 per share for aggregate gross proceeds of approximately $55.0 million, before deducting underwriting discounts and commissions and offering expenses.

Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10, 2023, at 5:20 p.m. ET / 2:20 p.m. PT.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that the company will release financial results for the first quarter 2023 after the market close on Wednesday, May 10, 2023.

Cytokinetics, Incorporated announced that its Annual Meeting of Stockholders will be held on Wednesday, May 10, 2023 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA.

Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, provided a corporate update and reported financial results for the quarter ended March 31, 2023.

electroCore, Inc., a commercial-stage bioelectronic medicine company and wellness company, announced first quarter 2023 financial results and provided an operational update.